Top

International Urogynecology Journal

Published in:

01-11-2009 | Original Article

Anticholinergic drug use for overactive bladder in Sweden: a nationwide pharmacoepidemiological study

Authors: Daniel Altman, Fredrik Granath, Anders Mattiasson, Christian Falconer

Published in: International Urogynecology Journal | Issue 11/2009

Abstract

Introduction and hypothesis

Nationwide use and costs of anticholinergic drug for overactive bladder are unknown.

Methods

We performed a nationwide study based on the Swedish Register on Prescribed Pharmaceuticals.

Results

From 2000 to 2007, there was a 68.8% increase in dispensed anticholinergic drugs in a population of 9 million. More than 93 million DDDs (calculated average maintenance dose per day) of anticholinergic drugs were dispensed corresponding to an overall DDD/TID (DDD per 1,000 inhabitants per day) of 3.5 per 1,000 persons per year. Approximately two thirds of anticholinergic drugs were prescribed to women, regardless of drug type. In 2007, the cost for anticholinergic drugs was 22 million € of which tolterodine comprised 70.8%. Solifenacin and darifenacin steadily increased their DDD/TIDs after market introduction.

Conclusions

In this nationwide study, there was a 70% increased rate of expedited prescriptions of anticholinergic drugs for the treatment of overactive bladder in a relatively stable population.

Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A (2002) The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21:167–178CrossRefPubMed

Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, Abrams P (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50:1306–1315CrossRefPubMed

Andersson KE (2004) Antimuscarinics for treatment of overactive bladder. Lancet Neurol 3:46–53CrossRefPubMed

Abrams P, Andersson KE (2007) Muscarinic receptor antagonists for overactive bladder. BJU Int 100:987–1006PubMed

Nilvebrant L, Hallen B, Larsson G (1997) Tolterodine—a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data. Life Sci 60:1129–1136CrossRefPubMed

Andersson KE, Chapple CR (2001) Oxybutynin and the overactive bladder. World J Urol 19:319–323CrossRefPubMed

Kay GG, Wesnes KA (2005) Pharmacodynamic effects of darifenacin, a muscarinic M selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers. BJU Int 96:1055–1062CrossRefPubMed

Masunaga K, Yoshida M, Inadome A, Murakami S, Sugiyama Y, Satoji Y, Maeda Y, Ueda S (2008) Pharmacological effects of solifenacin on human isolated urinary bladder. Pharmacology 82:43–52CrossRefPubMed

Cramer JA (2004) A systematic review of adherence with medications for diabetes. Diabetes care 27:1218–1224CrossRefPubMed

10.

Krigsman K, Nilsson JL, Ring L (2007) Adherence to multiple drug therapies: refill adherence to concomitant use of diabetes and asthma/COPD medication. Pharmacoepidemiol Drug Saf 16:1120–1128CrossRefPubMed

11.

Kelleher CJ, Cardozo LD, Khullar V, Salvatore S (1997) A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol 104:988–993PubMed

12.

Irwin DE, Milsom I, Kopp Z, Abrams P (2008) Symptom bother and health care-seeking behavior among individuals with overactive bladder. Eur Urol 53:1029–1037CrossRefPubMed

13.

Chapple CR (2004) Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician. BJU Int 94:738–744CrossRefPubMed

14.

Davila GW, Starkman JS, Dmochowski RR (2006) Transdermal oxybutynin for overactive bladder. Urol Clin North Am 33:455–463CrossRefPubMed

15.

Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J (2006) Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev (3):CD003781.

16.

Andersson KE (2007) LUTS treatment: future treatment options. Neurourol Urodyn 26:934–947CrossRefPubMed

17.

Kay GG, Granville LJ (2005) Antimuscarinic agents: implications and concerns in the management of overactive bladder in the elderly. Clin Ther 27:127–138CrossRefPubMed

Title: Anticholinergic drug use for overactive bladder in Sweden: a nationwide pharmacoepidemiological study
Authors: Daniel Altman
Fredrik Granath
Anders Mattiasson
Christian Falconer
Publication date: 01-11-2009
Publisher: Springer-Verlag
Published in: International Urogynecology Journal / Issue 11/2009
Print ISSN: 0937-3462
Electronic ISSN: 1433-3023
DOI: https://doi.org/10.1007/s00192-009-0957-z

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Anticholinergic drug use for overactive bladder in Sweden: a nationwide pharmacoepidemiological study

Abstract

Introduction and hypothesis

Methods

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Introduction and hypothesis

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2009

Structured hands-on training in repair of obstetric anal sphincter injuries (OASIS): an audit of clinical practice

Kari Bø, Bary Berghmans, Siv Mørkved, Marijke Van Kampen (eds): Evidence-Based Physical Therapy for the Pelvic Floor: Bridging Science and Clinical Practice

Outside–in transobturator midurethral sling and the dorsal nerve of the clitoris

Measurement of detrusor wall thickness in women with overactive bladder by transvaginal and transabdominal sonography

The effectiveness of surgical correction of uterine prolapse: cervical amputation with uterosacral ligament plication (modified Manchester) versus vaginal hysterectomy with high uterosacral ligament plication

A tumor of an ectopic ureter mimicking uterine cervix adenocarcinoma: case report and brief review